Charles Schwab Investment Management Inc Bolt Biotherapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$1.29 - $1.66 $31,878 - $41,021	24,712 New	24,712 $34,000
Q2 2022 Aug 15, 2022	SELL	$1.41 - $2.91 $71,706 - $147,990	-50,856 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$2.74 - $4.82 $11,392 - $20,041	-4,158 Reduced 7.56%	50,856 $140,000
Q4 2021 Feb 11, 2022	BUY	$4.19 - $13.97 $11,095 - $36,992	2,648 Added 5.06%	55,014 $270,000
Q3 2021 Nov 16, 2021	SELL	$11.15 - $18.6 $273,331 - $455,960	-24,514 Reduced 31.89%	52,366 $663,000
Q2 2021 Aug 16, 2021	SELL	$15.4 - $31.46 $61,461 - $125,556	-3,991 Reduced 4.94%	76,880 $1.19 Million
Q1 2021 May 17, 2021	BUY	$25.86 - $39.93 $2.09 Million - $3.23 Million	80,871 New	80,871 $2.66 Million

23M

Ticker BOLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,641,500
Market Cap $23.3M
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.